

1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Gore Range Capital Fund III | May 2026 | $250M | $70M | 1 |
| Gore Range Capital Fund II | December 2020 | $100M | $1.1M | 2 |
| Gore Range Capital Venture IV | September 2020 | $750,000 | $450,000 | 3 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Ethan Rigel | Selective | Medical devices, Biotech & pharma, Crypto & web3 | 8 | 2 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of Gore Range Capital’s own portfolio companies, based on 5 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Gore Range Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
No other firm shares a filed board seat with Gore Range Capital yet. That is a gap in what we have read, not a claim that Gore Range Capital invests alone.
A shared board seat: a company where filings name a Gore Range Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.